drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00366 | DB00633 | 1,594 | 614 | [
"DDInter600",
"DDInter520"
] | Doxylamine | Dexmedetomidine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. | Moderate | 1 | [
[
[
1594,
24,
614
]
],
[
[
1594,
21,
28695
],
[
28695,
60,
614
]
],
[
[
1594,
24,
222
],
[
222,
63,
614
]
],
[
[
1594,
63,
1648
],
[
1648,... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexmedetomidine"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is c... | Doxylamine (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Dexmedetomidine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with De... |
DB09046 | DB15328 | 1,094 | 829 | [
"DDInter1201",
"DDInter1896"
] | Metreleptin | Ubrogepant | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
1094,
24,
829
]
],
[
[
1094,
24,
1476
],
[
1476,
24,
829
]
],
[
[
1094,
63,
578
],
[
578,
24,
829
]
],
[
[
1094,
24,
384
],
[
384,
... | [
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Tica... |
DB00065 | DB00488 | 581 | 196 | [
"DDInter923",
"DDInter57"
] | Infliximab | Altretamine | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Major | 2 | [
[
[
581,
25,
196
]
],
[
[
581,
25,
139
],
[
139,
63,
196
]
],
[
[
581,
64,
1184
],
[
1184,
24,
196
]
],
[
[
581,
24,
496
],
[
496,
6... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Altretamine"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} ... | Infliximab may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Altretamine
Infliximab may lead to a major life threatening interaction when taken with Anakinra and Anakinra may cause a moderate interac... |
DB00254 | DB09154 | 964 | 1,475 | [
"DDInter598",
"DDInter1686"
] | Doxycycline | Sodium citrate | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Moderate | 1 | [
[
[
964,
24,
1475
]
],
[
[
964,
24,
1252
],
[
1252,
23,
1475
]
],
[
[
964,
24,
428
],
[
428,
63,
1475
]
],
[
[
964,
24,
1096
],
[
1096,
... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Fe... |
DB00668 | DB00902 | 874 | 104 | [
"DDInter652",
"DDInter1168"
] | Epinephrine | Methdilazine | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
874,
24,
104
]
],
[
[
874,
24,
820
],
[
820,
1,
104
]
],
[
[
874,
63,
508
],
[
508,
1,
104
]
],
[
[
874,
24,
401
],
[
401,
63,
... | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Methdilazine (Comp... |
DB00818 | DB13074 | 898 | 877 | [
"DDInter1538",
"DDInter1110"
] | Propofol | Macimorelin | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
898,
24,
877
]
],
[
[
898,
23,
112
],
[
112,
23,
877
]
],
[
[
898,
24,
913
],
[
913,
24,
877
]
],
[
[
898,
63,
485
],
[
485,
25,... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Propofol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Propofol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalut... |
DB01142 | DB08881 | 1,264 | 868 | [
"DDInter593",
"DDInter1925"
] | Doxepin | Vemurafenib | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
1264,
25,
868
]
],
[
[
1264,
6,
8374
],
[
8374,
45,
868
]
],
[
[
1264,
7,
6952
],
[
6952,
46,
868
]
],
[
[
1264,
18,
9384
],
[
9384,
... | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Doxepin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafenib"... | Doxepin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Doxepin (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Vemurafenib (Compound)
Doxepin (Compound) downregulates TRIB3 (Gene) and TRIB3 (Gene) is upregulated by Vemurafenib (Compound)
Doxepin (Compound) d... |
DB01242 | DB11703 | 1,237 | 405 | [
"DDInter410",
"DDInter9"
] | Clomipramine | Acalabrutinib | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
1237,
24,
405
]
],
[
[
1237,
25,
982
],
[
982,
63,
405
]
],
[
[
1237,
24,
1297
],
[
1297,
63,
405
]
],
[
[
1237,
63,
918
],
[
918,
... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Clomipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivo... | Clomipramine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat... |
DB00158 | DB00555 | 356 | 706 | [
"DDInter771",
"DDInter1020"
] | Folic acid | Lamotrigine | Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic aci... | Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It... | Moderate | 1 | [
[
[
356,
24,
706
]
],
[
[
356,
24,
1275
],
[
1275,
1,
706
]
],
[
[
356,
21,
28769
],
[
28769,
60,
706
]
],
[
[
356,
35,
663
],
[
663,
... | [
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lamotrigine"
]
],
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamterene"
],
[
... | Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Triamterene and Triamterene (Compound) resembles Lamotrigine (Compound)
Folic acid (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Lamotrigine (Compound)
Folic acid (Compound) rese... |
DB00041 | DB01059 | 1,648 | 956 | [
"DDInter38",
"DDInter1313"
] | Aldesleukin | Norfloxacin | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Minor | 0 | [
[
[
1648,
23,
956
]
],
[
[
1648,
23,
872
],
[
872,
40,
956
]
],
[
[
1648,
23,
1176
],
[
1176,
1,
956
]
],
[
[
1648,
24,
1307
],
[
1307,
... | [
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
[
... | Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Co... |
DB01017 | DB14730 | 1,669 | 1,412 | [
"DDInter1224",
"DDInter264"
] | Minocycline | Calaspargase pegol | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1669,
24,
1412
]
],
[
[
1669,
64,
640
],
[
640,
24,
1412
]
],
[
[
1669,
63,
322
],
[
322,
24,
1412
]
],
[
[
1669,
24,
850
],
[
850,
... | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Minocycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acitretin"
],
[
"A... | Minocycline may lead to a major life threatening interaction when taken with Acitretin and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin ma... |
DB00188 | DB01097 | 168 | 1,377 | [
"DDInter222",
"DDInter1033"
] | Bortezomib | Leflunomide | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
168,
25,
1377
]
],
[
[
168,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
168,
18,
2049
],
[
2049,
57,
1377
]
],
[
[
168,
7,
8386
],
[
8386,
... | [
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Bortezomib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Leflun... | Bortezomib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Bortezomib (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Leflunomide (Compound)
Bortezomib (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Leflunomide (Compound)
Borte... |
DB00988 | DB01105 | 817 | 222 | [
"DDInter584",
"DDInter1665"
] | Dopamine | Sibutramine | One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
817,
24,
222
]
],
[
[
817,
6,
6112
],
[
6112,
45,
222
]
],
[
[
817,
21,
28658
],
[
28658,
60,
222
]
],
[
[
817,
24,
659
],
[
659,
... | [
[
[
"Dopamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Dopamine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A4"
],
[
"SLC6A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Dopamine (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Sibutramine (Compound)
Dopamine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Sibutramine (Compound)
Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol... |
DB00196 | DB00286 | 600 | 380 | [
"DDInter743",
"DDInter439"
] | Fluconazole | Conjugated estrogens | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | Moderate | 1 | [
[
[
600,
24,
380
]
],
[
[
600,
24,
559
],
[
559,
1,
380
]
],
[
[
600,
24,
35
],
[
35,
40,
380
]
],
[
[
600,
6,
8374
],
[
8374,
45,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated estrogens"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone"
],... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Estrone and Estrone (Compound) resembles Conjugated estrogens (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol (Compound) resembles Conjugated estro... |
DB00350 | DB00647 | 1,214 | 675 | [
"DDInter1226",
"DDInter528"
] | Minoxidil | Dextropropoxyphene | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Moderate | 1 | [
[
[
1214,
24,
675
]
],
[
[
1214,
24,
1164
],
[
1164,
1,
675
]
],
[
[
1214,
24,
820
],
[
820,
64,
675
]
],
[
[
1214,
63,
576
],
[
576,
... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Dextropropoxyphene (Compound)
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may lead to a major life threat... |
DB00798 | DB01250 | 1,132 | 712 | [
"DDInter815",
"DDInter1334"
] | Gentamicin | Olsalazine | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inf... | Moderate | 1 | [
[
[
1132,
24,
712
]
],
[
[
1132,
63,
50
],
[
50,
40,
712
]
],
[
[
1132,
24,
914
],
[
914,
24,
712
]
],
[
[
1132,
35,
416
],
[
416,
2... | [
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
],
[... | Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Olsalazine (Compound)
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause a moderate interaction that... |
DB01023 | DB08946 | 409 | 512 | [
"DDInter716",
"DDInter962"
] | Felodipine | Iopanoic acid | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Iopanoic acid contains iodine and is useful as a contrast medium in cholecystography. | Moderate | 1 | [
[
[
409,
24,
512
]
],
[
[
409,
40,
1428
],
[
1428,
24,
512
]
],
[
[
409,
1,
336
],
[
336,
24,
512
]
],
[
[
409,
24,
1527
],
[
1527,
... | [
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopanoic acid"
]
],
[
[
"Felodipine",
"{u} (Compound) resembles {v} (Compound)",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a mode... | Felodipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid
Felodipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic... |
DB00377 | DB12332 | 1,494 | 1,619 | [
"DDInter1382",
"DDInter1626"
] | Palonosetron | Rucaparib | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1494,
24,
1619
]
],
[
[
1494,
25,
222
],
[
222,
23,
1619
]
],
[
[
1494,
23,
112
],
[
112,
23,
1619
]
],
[
[
1494,
25,
87
],
[
87,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutr... | Palonosetron may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may... |
DB00358 | DB00938 | 1,010 | 455 | [
"DDInter1140",
"DDInter1635"
] | Mefloquine | Salmeterol | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
1010,
24,
455
]
],
[
[
1010,
24,
1523
],
[
1523,
25,
455
]
],
[
[
1010,
24,
688
],
[
688,
63,
455
]
],
[
[
1010,
6,
8374
],
[
8374,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may lead to a major life threatening interaction when taken with Salmeterol
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a ... |
DB00014 | DB00656 | 521 | 827 | [
"DDInter839",
"DDInter1851"
] | Goserelin | Trazodone | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Moderate | 1 | [
[
[
521,
24,
827
]
],
[
[
521,
24,
623
],
[
623,
40,
827
]
],
[
[
521,
24,
1630
],
[
1630,
1,
827
]
],
[
[
521,
25,
695
],
[
695,
1,... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
],
[
... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Trazodone (Compound)
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Trazodone (Compound)
... |
DB00008 | DB00531 | 491 | 450 | [
"DDInter1407",
"DDInter456"
] | Peginterferon alfa-2a | Cyclophosphamide | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Minor | 0 | [
[
[
491,
23,
450
]
],
[
[
491,
24,
268
],
[
268,
23,
450
]
],
[
[
491,
24,
1593
],
[
1593,
63,
450
]
],
[
[
491,
24,
589
],
[
589,
2... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"P... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide
Peginterferon alfa-2a may cause a moderate interaction that could exacerbat... |
DB05239 | DB08901 | 866 | 1,468 | [
"DDInter425",
"DDInter1492"
] | Cobimetinib | Ponatinib | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
866,
24,
1468
]
],
[
[
866,
63,
478
],
[
478,
24,
1468
]
],
[
[
866,
63,
752
],
[
752,
23,
1468
]
],
[
[
866,
64,
307
],
[
307,
... | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetid... |
DB09054 | DB12141 | 384 | 971 | [
"DDInter905",
"DDInter817"
] | Idelalisib | Gilteritinib | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
384,
25,
971
]
],
[
[
384,
64,
1135
],
[
1135,
23,
971
]
],
[
[
384,
63,
1247
],
[
1247,
23,
971
]
],
[
[
384,
24,
466
],
[
466,
... | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} m... | Idelalisib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole ... |
DB00363 | DB01010 | 695 | 61 | [
"DDInter419",
"DDInter622"
] | Clozapine | Edrophonium | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. | Moderate | 1 | [
[
[
695,
24,
61
]
],
[
[
695,
25,
1011
],
[
1011,
63,
61
]
],
[
[
695,
24,
1511
],
[
1511,
63,
61
]
],
[
[
695,
24,
1507
],
[
1507,
... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod"... | Clozapine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause... |
DB00928 | DB06643 | 1,426 | 1,136 | [
"DDInter148",
"DDInter500"
] | Azacitidine | Denosumab | Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. ... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
1426,
24,
1136
]
],
[
[
1426,
25,
1377
],
[
1377,
24,
1136
]
],
[
[
1426,
25,
1510
],
[
1510,
63,
1136
]
],
[
[
1426,
24,
270
],
[
270... | [
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Azacitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunom... | Azacitidine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Azacitidine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a mode... |
DB00834 | DB01001 | 932 | 688 | [
"DDInter1215",
"DDInter1632"
] | Mifepristone | Salbutamol | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Major | 2 | [
[
[
932,
25,
688
]
],
[
[
932,
24,
455
],
[
455,
24,
688
]
],
[
[
932,
25,
1148
],
[
1148,
63,
688
]
],
[
[
932,
6,
8374
],
[
8374,
... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salbutamol"
]
],
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmet... | Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Mifepristone may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline ma... |
DB11943 | DB14491 | 255 | 428 | [
"DDInter495",
"DDInter725"
] | Delafloxacin | Ferrous fumarate | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
255,
24,
428
]
],
[
[
255,
63,
1096
],
[
1096,
23,
428
]
],
[
[
255,
63,
1384
],
[
1384,
24,
428
]
],
[
[
255,
63,
1096
],
[
1096,
... | [
[
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid... | Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00055 | DB15035 | 834 | 503 | [
"DDInter605",
"DDInter1959"
] | Drotrecogin alfa | Zanubrutinib | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Major | 2 | [
[
[
834,
25,
503
]
],
[
[
834,
24,
222
],
[
222,
24,
503
]
],
[
[
834,
25,
39
],
[
39,
25,
503
]
],
[
[
834,
64,
25
],
[
25,
25,
... | [
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Drotrecogin alfa may lead to a major life threatening interaction when taken with Panobinostat and Pan... |
DB00468 | DB01764 | 1,424 | 805 | [
"DDInter1557",
"DDInter469"
] | Quinine | Dalfopristin | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Moderate | 1 | [
[
[
1424,
24,
805
]
],
[
[
1424,
6,
8374
],
[
8374,
45,
805
]
],
[
[
1424,
63,
1101
],
[
1101,
23,
805
]
],
[
[
1424,
24,
283
],
[
283,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Quinine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dalfopristin
Quinine may cause a mo... |
DB06288 | DB11986 | 607 | 484 | [
"DDInter77",
"DDInter648"
] | Amisulpride | Entrectinib | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
607,
25,
484
]
],
[
[
607,
62,
112
],
[
112,
23,
484
]
],
[
[
607,
25,
774
],
[
774,
24,
484
]
],
[
[
607,
24,
1662
],
[
1662,
2... | [
[
[
"Amisulpride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Amisulpride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Amisulpride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Amisulpride may lead to a major life threatening interaction when taken with Degarelix and Degarelix may cau... |
DB00569 | DB12500 | 553 | 283 | [
"DDInter775",
"DDInter714"
] | Fondaparinux | Fedratinib | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
553,
25,
283
]
],
[
[
553,
25,
885
],
[
885,
24,
283
]
],
[
[
553,
63,
529
],
[
529,
24,
283
]
],
[
[
553,
24,
1237
],
[
1237,
2... | [
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
... | Fondaparinux may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine ... |
DB00532 | DB00792 | 208 | 832 | [
"DDInter1152",
"DDInter1878"
] | Mephenytoin | Tripelennamine | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
208,
24,
832
]
],
[
[
208,
24,
100
],
[
100,
63,
832
]
],
[
[
208,
24,
649
],
[
649,
1,
832
]
],
[
[
208,
63,
1594
],
[
1594,
24... | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Clofe... |
DB00959 | DB09118 | 1,486 | 1,580 | [
"DDInter1191",
"DDInter1711"
] | Methylprednisolone | Stiripentol | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
1486,
24,
1580
]
],
[
[
1486,
24,
283
],
[
283,
63,
1580
]
],
[
[
1486,
63,
473
],
[
473,
24,
1580
]
],
[
[
1486,
62,
1018
],
[
1018,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Repa... |
DB00477 | DB01259 | 216 | 392 | [
"DDInter363",
"DDInter1024"
] | Chlorpromazine | Lapatinib | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
216,
24,
392
]
],
[
[
216,
6,
4973
],
[
4973,
45,
392
]
],
[
[
216,
21,
28852
],
[
28852,
60,
392
]
],
[
[
216,
23,
112
],
[
112,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compou... | Chlorpromazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Chlorpromazine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Lapatinib (Compound)
Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Metronidazo... |
DB01030 | DB08904 | 869 | 375 | [
"DDInter1835",
"DDInter342"
] | Topotecan | Certolizumab pegol | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
869,
25,
375
]
],
[
[
869,
63,
1461
],
[
1461,
23,
375
]
],
[
[
869,
24,
200
],
[
200,
63,
375
]
],
[
[
869,
24,
1593
],
[
1593,
... | [
[
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitam... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans an... |
DB00188 | DB14730 | 168 | 1,412 | [
"DDInter222",
"DDInter264"
] | Bortezomib | Calaspargase pegol | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
168,
24,
1412
]
],
[
[
168,
24,
1439
],
[
1439,
24,
1412
]
],
[
[
168,
23,
868
],
[
868,
24,
1412
]
],
[
[
168,
63,
268
],
[
268,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Vemurafenib and... |
DB00069 | DB05528 | 367 | 1,070 | [
"DDInter946",
"DDInter1228"
] | Interferon alfacon-1 | Mipomersen | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
367,
25,
1070
]
],
[
[
367,
24,
14
],
[
14,
25,
1070
]
],
[
[
367,
24,
350
],
[
350,
64,
1070
]
],
[
[
367,
63,
581
],
[
581,
25... | [
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may lead to a major life threatening interaction when taken with Mipomersen
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib ... |
DB00468 | DB08868 | 1,424 | 1,011 | [
"DDInter1557",
"DDInter737"
] | Quinine | Fingolimod | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1424,
25,
1011
]
],
[
[
1424,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
1424,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
1424,
23,
1247
],
[
... | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fingolimod"
... | Quinine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Quinine (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Quinine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and... |
DB00559 | DB11827 | 152 | 433 | [
"DDInter223",
"DDInter669"
] | Bosentan | Ertugliflozin | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
152,
24,
433
]
],
[
[
152,
24,
959
],
[
959,
24,
433
]
],
[
[
152,
63,
251
],
[
251,
24,
433
]
],
[
[
152,
24,
1033
],
[
1033,
6... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betame... |
DB00334 | DB01218 | 867 | 1,493 | [
"DDInter1326",
"DDInter852"
] | Olanzapine | Halofantrine | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Moderate | 1 | [
[
[
867,
24,
1493
]
],
[
[
867,
6,
12523
],
[
12523,
45,
1493
]
],
[
[
867,
23,
112
],
[
112,
23,
1493
]
],
[
[
867,
24,
770
],
[
770,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
]
],
[
[
"Olanzapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)... | Olanzapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Halofantrine (Compound)
Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Halofantrine
Olanzapine m... |
DB00515 | DB00987 | 589 | 1,224 | [
"DDInter387",
"DDInter460"
] | Cisplatin | Cytarabine | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Moderate | 1 | [
[
[
589,
24,
1224
]
],
[
[
589,
5,
11555
],
[
11555,
44,
1224
]
],
[
[
589,
6,
8803
],
[
8803,
45,
1224
]
],
[
[
589,
6,
7720
],
[
7720,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Cisplatin",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease)... | Cisplatin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Cytarabine (Compound)
Cisplatin (Compound) binds SLC22A2 (Gene) and SLC22A2 (Gene) is bound by Cytarabine (Compound)
Cisplatin (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Cytarabine (Compound)
Ci... |
DB04868 | DB10276 | 478 | 1,624 | [
"DDInter1293",
"DDInter1623"
] | Nilotinib | Rotavirus vaccine | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
478,
25,
1624
]
],
[
[
478,
63,
617
],
[
617,
24,
1624
]
],
[
[
478,
63,
770
],
[
770,
25,
1624
]
],
[
[
478,
64,
51
],
[
51,
25... | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budes... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and ... |
DB00461 | DB00877 | 598 | 629 | [
"DDInter1254",
"DDInter1678"
] | Nabumetone | Sirolimus | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Major | 2 | [
[
[
598,
25,
629
]
],
[
[
598,
18,
2060
],
[
2060,
46,
629
]
],
[
[
598,
21,
28898
],
[
28898,
60,
629
]
],
[
[
598,
24,
167
],
[
167,
... | [
[
[
"Nabumetone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Nabumetone",
"{u} (Compound) downregulates {v} (Gene)",
"PIK3CA"
],
[
"PIK3CA",
"{u} (Gene) is upregulated by {v} (Compound)",
... | Nabumetone (Compound) downregulates PIK3CA (Gene) and PIK3CA (Gene) is upregulated by Sirolimus (Compound)
Nabumetone (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Sirolimus (Compound)
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with H... |
DB01238 | DB11978 | 673 | 124 | [
"DDInter118",
"DDInter822"
] | Aripiprazole | Glasdegib | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
673,
24,
124
]
],
[
[
673,
62,
112
],
[
112,
23,
124
]
],
[
[
673,
64,
475
],
[
475,
24,
124
]
],
[
[
673,
63,
79
],
[
79,
24,
... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Aripiprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Aripiprazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Aripiprazole may lead to a major life threatening interaction when taken with Morphine and Morphine may cause... |
DB00860 | DB14783 | 891 | 287 | [
"DDInter1513",
"DDInter574"
] | Prednisolone | Diroximel fumarate | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
891,
24,
287
]
],
[
[
891,
63,
1101
],
[
1101,
24,
287
]
],
[
[
891,
24,
384
],
[
384,
24,
287
]
],
[
[
891,
40,
1220
],
[
1220,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisi... |
DB06168 | DB15719 | 1,531 | 487 | [
"DDInter281",
"DDInter171"
] | Canakinumab | Belantamab mafodotin | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF). Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma; however, its manufa... | Moderate | 1 | [
[
[
1531,
24,
487
]
],
[
[
1531,
24,
259
],
[
259,
24,
487
]
],
[
[
1531,
63,
4
],
[
4,
24,
487
]
],
[
[
1531,
25,
976
],
[
976,
25,... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belantamab mafodotin"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
... | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Belantamab mafodotin
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxi... |
DB00312 | DB01233 | 1,023 | 1,311 | [
"DDInter1423",
"DDInter1197"
] | Pentobarbital | Metoclopramide | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1023,
24,
1311
]
],
[
[
1023,
24,
1151
],
[
1151,
40,
1311
]
],
[
[
1023,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
1023,
24,
1010
],
[
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib (Compound) resembles Metoclopramide (Compound)
Pentobarbital (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Pentobarbital may cause a mode... |
DB00570 | DB09073 | 147 | 951 | [
"DDInter1936",
"DDInter1379"
] | Vinblastine | Palbociclib | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
147,
24,
951
]
],
[
[
147,
24,
496
],
[
496,
63,
951
]
],
[
[
147,
24,
259
],
[
259,
24,
951
]
],
[
[
147,
63,
134
],
[
134,
24,... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00347 | DB01233 | 917 | 1,311 | [
"DDInter1871",
"DDInter1197"
] | Trimethadione | Metoclopramide | An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378) | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
917,
24,
1311
]
],
[
[
917,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
917,
24,
1010
],
[
1010,
23,
1311
]
],
[
[
917,
24,
662
],
[
662,
... | [
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Trimethadione",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Eff... | Trimethadione (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a minor interaction that can limit clinical effects when taken wi... |
DB00938 | DB11652 | 455 | 1,155 | [
"DDInter1635",
"DDInter1891"
] | Salmeterol | Tucatinib | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Major | 2 | [
[
[
455,
25,
1155
]
],
[
[
455,
24,
222
],
[
222,
23,
1155
]
],
[
[
455,
63,
1424
],
[
1424,
24,
1155
]
],
[
[
455,
24,
659
],
[
659,
... | [
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramin... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine ma... |
DB00328 | DB09481 | 831 | 460 | [
"DDInter921",
"DDInter1113"
] | Indomethacin | Magnesium carbonate | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Minor | 0 | [
[
[
831,
23,
460
]
],
[
[
831,
23,
752
],
[
752,
23,
460
]
],
[
[
831,
63,
1018
],
[
1018,
23,
460
]
],
[
[
831,
25,
1468
],
[
1468,
... | [
[
[
"Indomethacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Indomethacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],... | Indomethacin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine ... |
DB01175 | DB09330 | 318 | 985 | [
"DDInter672",
"DDInter1352"
] | Escitalopram | Osimertinib | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
318,
25,
985
]
],
[
[
318,
62,
168
],
[
168,
23,
985
]
],
[
[
318,
23,
1478
],
[
1478,
24,
985
]
],
[
[
318,
63,
480
],
[
480,
2... | [
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezo... | Escitalopram may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Ivacaftor and Ivacafto... |
DB00740 | DB08881 | 424 | 868 | [
"DDInter1596",
"DDInter1925"
] | Riluzole | Vemurafenib | A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
424,
24,
868
]
],
[
[
424,
6,
17404
],
[
17404,
45,
868
]
],
[
[
424,
6,
16740
],
[
16740,
46,
868
]
],
[
[
424,
7,
18110
],
[
18110,
... | [
[
[
"Riluzole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Riluzole",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
... | Riluzole (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Vemurafenib (Compound)
Riluzole (Compound) binds SLC7A11 (Gene) and SLC7A11 (Gene) is upregulated by Vemurafenib (Compound)
Riluzole (Compound) upregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is upregulated by Vemurafenib (Compound)
Riluzole (Compo... |
DB00673 | DB06335 | 723 | 761 | [
"DDInter112",
"DDInter1646"
] | Aprepitant | Saxagliptin | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
723,
24,
761
]
],
[
[
723,
6,
7524
],
[
7524,
45,
761
]
],
[
[
723,
21,
28966
],
[
28966,
60,
761
]
],
[
[
723,
23,
307
],
[
307,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Aprepitant",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)"... | Aprepitant (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Saxagliptin (Compound)
Aprepitant (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Saxagliptin (Compound)
Aprepitant may cause a minor interaction that can limit clin... |
DB00819 | DB09043 | 471 | 135 | [
"DDInter15",
"DDInter36"
] | Acetazolamide | Albiglutide | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
471,
24,
135
]
],
[
[
471,
63,
1647
],
[
1647,
23,
135
]
],
[
[
471,
63,
870
],
[
870,
24,
135
]
],
[
[
471,
24,
688
],
[
688,
2... | [
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
... | Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and ... |
DB00030 | DB00850 | 1,685 | 1,630 | [
"DDInter934",
"DDInter1432"
] | Insulin human | Perphenazine | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Moderate | 1 | [
[
[
1685,
24,
1630
]
],
[
[
1685,
24,
673
],
[
673,
40,
1630
]
],
[
[
1685,
24,
417
],
[
417,
23,
1630
]
],
[
[
1685,
24,
549
],
[
549,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole (Compound) resembles Perphenazine (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction t... |
DB00081 | DB08816 | 273 | 578 | [
"DDInter1838",
"DDInter1802"
] | Tositumomab | Ticagrelor | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
273,
24,
578
]
],
[
[
273,
23,
539
],
[
539,
62,
578
]
],
[
[
273,
25,
1011
],
[
1011,
62,
578
]
],
[
[
273,
64,
1578
],
[
1578,
... | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Tositumomab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
... | Tositumomab may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Tositumomab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a mino... |
DB00681 | DB01336 | 1,287 | 545 | [
"DDInter85",
"DDInter1198"
] | Amphotericin B | Metocurine | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant. Patients on chronic anticonvulsant drugs are relatively resistant to metocurine. | Moderate | 1 | [
[
[
1287,
24,
545
]
],
[
[
1287,
24,
1217
],
[
1217,
40,
545
]
],
[
[
1287,
63,
91
],
[
91,
24,
545
]
],
[
[
1287,
24,
1486
],
[
1486,
... | [
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metocurine"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tubocurarine"
]... | Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Tubocurarine and Tubocurarine (Compound) resembles Metocurine (Compound)
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may cause a moderate interactio... |
DB00652 | DB06282 | 234 | 516 | [
"DDInter1421",
"DDInter1053"
] | Pentazocine | Levocetirizine | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
234,
24,
516
]
],
[
[
234,
63,
701
],
[
701,
24,
516
]
],
[
[
234,
25,
407
],
[
407,
63,
516
]
],
[
[
234,
24,
1219
],
[
1219,
2... | [
[
[
"Pentazocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Pentazocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Pentazocine may lead to a major life threatening interaction when taken with Opium and Opium may cause a mo... |
DB00899 | DB09241 | 411 | 1,629 | [
"DDInter1579",
"DDInter1186"
] | Remifentanil | Methylene blue | Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depress... | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Major | 2 | [
[
[
411,
25,
1629
]
],
[
[
411,
24,
1311
],
[
1311,
24,
1629
]
],
[
[
411,
63,
73
],
[
73,
25,
1629
]
],
[
[
411,
40,
1454
],
[
1454,
... | [
[
[
"Remifentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Remifentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
... | Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Phent... |
DB01285 | DB08882 | 708 | 1,281 | [
"DDInter445",
"DDInter1070"
] | Corticotropin | Linagliptin | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
708,
24,
1281
]
],
[
[
708,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
708,
62,
1052
],
[
1052,
24,
1281
]
],
[
[
708,
63,
1236
],
[
1236,
... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Corticotropin may cause a minor interaction that can limit clinical effects when taken with Ritodrine and Ritodrine may cause a moderate interaction that co... |
DB01132 | DB09128 | 1,130 | 1,241 | [
"DDInter1472",
"DDInter231"
] | Pioglitazone | Brexpiprazole | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
1130,
24,
1241
]
],
[
[
1130,
24,
1296
],
[
1296,
63,
1241
]
],
[
[
1130,
63,
1179
],
[
1179,
24,
1241
]
],
[
[
1130,
24,
820
],
[
820... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with In... |
DB00662 | DB01192 | 717 | 560 | [
"DDInter1873",
"DDInter1372"
] | Trimethobenzamide | Oxymorphone | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). O... | Moderate | 1 | [
[
[
717,
24,
560
]
],
[
[
717,
63,
828
],
[
828,
1,
560
]
],
[
[
717,
24,
314
],
[
314,
1,
560
]
],
[
[
717,
21,
28817
],
[
28817,
6... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Oxymorphone (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine (Compound) resembles Oxymorpho... |
DB00375 | DB00641 | 1,037 | 467 | [
"DDInter433",
"DDInter1675"
] | Colestipol | Simvastatin | Bile acid sequestrants like colestipol have been in use since the 1970s.[FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally o... | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Moderate | 1 | [
[
[
1037,
24,
467
]
],
[
[
1037,
21,
28810
],
[
28810,
60,
467
]
],
[
[
1037,
63,
1152
],
[
1152,
23,
467
]
],
[
[
1037,
24,
542
],
[
542,... | [
[
[
"Colestipol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]
],
[
[
"Colestipol",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"... | Colestipol (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Simvastatin (Compound)
Colestipol may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a minor interaction that can limit clinical effe... |
DB08881 | DB09122 | 868 | 1,613 | [
"DDInter1925",
"DDInter1409"
] | Vemurafenib | Peginterferon beta-1a | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
868,
24,
1613
]
],
[
[
868,
63,
671
],
[
671,
24,
1613
]
],
[
[
868,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
868,
24,
975
],
[
975,
... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Cannab... |
DB00771 | DB01193 | 262 | 819 | [
"DDInter397",
"DDInter12"
] | Clidinium | Acebutolol | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Moderate | 1 | [
[
[
262,
24,
819
]
],
[
[
262,
24,
887
],
[
887,
1,
819
]
],
[
[
262,
63,
1121
],
[
1121,
1,
819
]
],
[
[
262,
24,
1511
],
[
1511,
6... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
],
[
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol and Bisoprolol (Compound) resembles Acebutolol (Compound)
Clidin... |
DB00704 | DB09078 | 267 | 1,228 | [
"DDInter1263",
"DDInter1036"
] | Naltrexone | Lenvatinib | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
267,
24,
1228
]
],
[
[
267,
24,
463
],
[
463,
23,
1228
]
],
[
[
267,
24,
609
],
[
609,
24,
1228
]
],
[
[
267,
63,
847
],
[
847,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
],
[
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clar... |
DB09074 | DB16582 | 1,362 | 899 | [
"DDInter1327",
"DDInter1080"
] | Olaparib | Lisocabtagene maraleucel | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel].[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. CAR T-cell therapy has ... | Moderate | 1 | [
[
[
1362,
24,
899
]
],
[
[
1362,
63,
440
],
[
440,
24,
899
]
],
[
[
1362,
24,
810
],
[
810,
24,
899
]
],
[
[
1362,
25,
676
],
[
676,
... | [
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisocabtagene maraleucel"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
]... | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Lisocabtagene maraleucel
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Strontium c... |
DB01611 | DB09065 | 1,487 | 760 | [
"DDInter893",
"DDInter424"
] | Hydroxychloroquine | Cobicistat | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
1487,
24,
760
]
],
[
[
1487,
63,
479
],
[
479,
23,
760
]
],
[
[
1487,
64,
1230
],
[
1230,
23,
760
]
],
[
[
1487,
24,
1374
],
[
1374,
... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
... | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Hydroxychloroquine may lead to a major life threatening interaction when taken with Citalopram and Citalopra... |
DB00827 | DB06723 | 646 | 115 | [
"DDInter383",
"DDInter58"
] | Cinoxacin | Aluminum hydroxide | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
646,
24,
115
]
],
[
[
646,
21,
28845
],
[
28845,
60,
115
]
],
[
[
646,
64,
870
],
[
870,
23,
115
]
],
[
[
646,
25,
891
],
[
891,
... | [
[
[
"Cinoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Cinoxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Effect) is caus... | Cinoxacin (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Aluminum hydroxide (Compound)
Cinoxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Aluminum hydro... |
DB00008 | DB01610 | 491 | 248 | [
"DDInter1407",
"DDInter1912"
] | Peginterferon alfa-2a | Valganciclovir | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
491,
24,
248
]
],
[
[
491,
24,
563
],
[
563,
1,
248
]
],
[
[
491,
25,
1101
],
[
1101,
24,
248
]
],
[
[
491,
24,
372
],
[
372,
24... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"G... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interacti... |
DB00420 | DB08907 | 508 | 1,344 | [
"DDInter1532",
"DDInter280"
] | Promazine | Canagliflozin | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
508,
24,
1344
]
],
[
[
508,
24,
549
],
[
549,
1,
1344
]
],
[
[
508,
6,
8374
],
[
8374,
45,
1344
]
],
[
[
508,
24,
1148
],
[
1148,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Promazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Canagliflozin (Compound)
Promazine may cause a moderate interaction that could ex... |
DB00553 | DB05294 | 92 | 1,069 | [
"DDInter1177",
"DDInter1917"
] | Methoxsalen | Vandetanib | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Moderate | 1 | [
[
[
92,
24,
1069
]
],
[
[
92,
63,
1195
],
[
1195,
40,
1069
]
],
[
[
92,
6,
8374
],
[
8374,
45,
1069
]
],
[
[
92,
21,
28883
],
[
28883,
... | [
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
... | Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib (Compound) resembles Vandetanib (Compound)
Methoxsalen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound)
Methoxsalen (Compound) causes Skin disorder (Side Effect) and Skin... |
DB00055 | DB01105 | 834 | 222 | [
"DDInter605",
"DDInter1665"
] | Drotrecogin alfa | Sibutramine | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
834,
24,
222
]
],
[
[
834,
25,
802
],
[
802,
63,
222
]
],
[
[
834,
25,
1027
],
[
1027,
24,
222
]
],
[
[
834,
64,
1432
],
[
1432,
... | [
[
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
],
[
... | Drotrecogin alfa may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Drotrecogin alfa may lead to a major life threatening interaction when taken with Piroxicam and Piroxicam may cause a mo... |
DB00317 | DB00631 | 883 | 372 | [
"DDInter810",
"DDInter405"
] | Gefitinib | Clofarabine | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
883,
24,
372
]
],
[
[
883,
6,
17404
],
[
17404,
45,
372
]
],
[
[
883,
18,
6896
],
[
6896,
45,
372
]
],
[
[
883,
18,
3222
],
[
3222,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
... | Gefitinib (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Clofarabine (Compound)
Gefitinib (Compound) downregulates RRM2 (Gene) and RRM2 (Gene) is bound by Clofarabine (Compound)
Gefitinib (Compound) downregulates DUSP4 (Gene) and DUSP4 (Gene) is upregulated by Clofarabine (Compound)
Gefitinib (Compound) upr... |
DB01010 | DB01591 | 61 | 667 | [
"DDInter622",
"DDInter1696"
] | Edrophonium | Solifenacin | A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
61,
24,
667
]
],
[
[
61,
21,
30015
],
[
30015,
60,
667
]
],
[
[
61,
63,
1123
],
[
1123,
24,
667
]
],
[
[
61,
24,
770
],
[
770,
2... | [
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Edrophonium",
"{u} (Compound) causes {v} (Side Effect)",
"Dysphonia"
],
[
"Dysphonia",
"{u} (Side Effect) is c... | Edrophonium (Compound) causes Dysphonia (Side Effect) and Dysphonia (Side Effect) is caused by Solifenacin (Compound)
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00017 | DB00295 | 1,505 | 475 | [
"DDInter1636",
"DDInter1244"
] | Salmon calcitonin | Morphine | Synthetic peptide, 32 residues long formulated as a nasal spray. | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Minor | 0 | [
[
[
1505,
23,
475
]
],
[
[
1505,
24,
1399
],
[
1399,
63,
475
]
],
[
[
1505,
23,
752
],
[
752,
63,
475
]
],
[
[
1505,
24,
1399
],
[
1399,
... | [
[
[
"Salmon calcitonin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Morphine"
]
],
[
[
"Salmon calcitonin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate... | Salmon calcitonin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Salmon calcitonin may cause a minor interaction that can limit clinical effects when taken wi... |
DB01175 | DB06822 | 318 | 802 | [
"DDInter672",
"DDInter1812"
] | Escitalopram | Tinzaparin | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Moderate | 1 | [
[
[
318,
24,
802
]
],
[
[
318,
64,
222
],
[
222,
24,
802
]
],
[
[
318,
40,
1230
],
[
1230,
24,
802
]
],
[
[
318,
25,
1151
],
[
1151,
... | [
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibut... | Escitalopram may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Escitalopram (Compound) resembles Citalopram (Compound) and Citalopram may cause a moderate interaction that could exacerba... |
DB12010 | DB14761 | 214 | 242 | [
"DDInter785",
"DDInter1578"
] | Fostamatinib | Remdesivir | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA. Recently, fosta... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
214,
24,
242
]
],
[
[
214,
63,
1130
],
[
1130,
24,
242
]
],
[
[
214,
64,
1377
],
[
1377,
24,
242
]
],
[
[
214,
24,
971
],
[
971,
... | [
[
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
... | Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Fostamatinib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide ... |
DB00771 | DB00985 | 262 | 1,443 | [
"DDInter397",
"DDInter562"
] | Clidinium | Dimenhydrinate | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyl... | Moderate | 1 | [
[
[
262,
24,
1443
]
],
[
[
262,
40,
11286
],
[
11286,
1,
1443
]
],
[
[
262,
24,
1376
],
[
1376,
63,
1443
]
],
[
[
262,
74,
357
],
[
357,
... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimenhydrinate"
]
],
[
[
"Clidinium",
"{u} (Compound) resembles {v} (Compound)",
"Diphenylpyraline"
],
[
"Diphenylpyraline",
"{u} (Comp... | Clidinium (Compound) resembles Diphenylpyraline (Compound) and Diphenylpyraline (Compound) resembles Dimenhydrinate (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases whe... |
DB01619 | DB14740 | 830 | 771 | [
"DDInter1441",
"DDInter881"
] | Phenindamine | Hyaluronidase | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permea... | Minor | 0 | [
[
[
830,
23,
771
]
],
[
[
830,
24,
849
],
[
849,
23,
771
]
],
[
[
830,
63,
1242
],
[
1242,
23,
771
]
],
[
[
830,
40,
104
],
[
104,
2... | [
[
[
"Phenindamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and C... |
DB00046 | DB11921 | 1,179 | 1,019 | [
"DDInter940",
"DDInter492"
] | Insulin lispro | Deflazacort | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
1179,
24,
1019
]
],
[
[
1179,
24,
1072
],
[
1072,
23,
1019
]
],
[
[
1179,
24,
192
],
[
192,
24,
1019
]
],
[
[
1179,
24,
1654
],
[
1654... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Esterified estro... |
DB00364 | DB00827 | 417 | 646 | [
"DDInter1717",
"DDInter383"
] | Sucralfate | Cinoxacin | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Moderate | 1 | [
[
[
417,
24,
646
]
],
[
[
417,
21,
28845
],
[
28845,
60,
646
]
],
[
[
417,
24,
433
],
[
433,
63,
646
]
],
[
[
417,
24,
127
],
[
127,
... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cinoxacin"
]
],
[
[
"Sucralfate",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Effect) is caused by {... | Sucralfate (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Cinoxacin (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Cinoxaci... |
DB00673 | DB12130 | 723 | 1,017 | [
"DDInter112",
"DDInter1094"
] | Aprepitant | Lorlatinib | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
723,
24,
1017
]
],
[
[
723,
63,
608
],
[
608,
23,
1017
]
],
[
[
723,
23,
271
],
[
271,
23,
1017
]
],
[
[
723,
62,
1101
],
[
1101,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron m... |
DB00041 | DB00356 | 1,648 | 1,315 | [
"DDInter38",
"DDInter366"
] | Aldesleukin | Chlorzoxazone | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) | Moderate | 1 | [
[
[
1648,
24,
1315
]
],
[
[
1648,
24,
267
],
[
267,
63,
1315
]
],
[
[
1648,
24,
1242
],
[
1242,
24,
1315
]
],
[
[
1648,
25,
770
],
[
770,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorzoxazone"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Chlorzoxazone
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and C... |
DB00970 | DB08913 | 0 | 1,186 | [
"DDInter466",
"DDInter1561"
] | Dactinomycin | Radium Ra 223 dichloride | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
0,
24,
1186
]
],
[
[
0,
21,
28872
],
[
28872,
60,
1186
]
],
[
[
0,
24,
37
],
[
37,
24,
1186
]
],
[
[
0,
63,
134
],
[
134,
24,
... | [
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Dactinomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Extravasation"
],
[
"Extravasation",
... | Dactinomycin (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases... |
DB09039 | DB11901 | 1,670 | 913 | [
"DDInter629",
"DDInter107"
] | Eliglustat | Apalutamide | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
1670,
25,
913
]
],
[
[
1670,
64,
271
],
[
271,
23,
913
]
],
[
[
1670,
64,
600
],
[
600,
24,
913
]
],
[
[
1670,
63,
1237
],
[
1237,
... | [
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} ... | Eliglustat may lead to a major life threatening interaction when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Eliglustat may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate int... |
DB00580 | DB00860 | 311 | 891 | [
"DDInter1910",
"DDInter1513"
] | Valdecoxib | Prednisolone | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
311,
24,
891
]
],
[
[
311,
24,
175
],
[
175,
40,
891
]
],
[
[
311,
24,
167
],
[
167,
1,
891
]
],
[
[
311,
63,
251
],
[
251,
1,
... | [
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Predni... |
DB00804 | DB06077 | 1,507 | 879 | [
"DDInter543",
"DDInter1102"
] | Dicyclomine | Lumateperone | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Moderate | 1 | [
[
[
1507,
24,
879
]
],
[
[
1507,
24,
407
],
[
407,
63,
879
]
],
[
[
1507,
24,
1511
],
[
1511,
24,
879
]
],
[
[
1507,
63,
999
],
[
999,
... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
... | Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate... |
DB09098 | DB12010 | 98 | 214 | [
"DDInter1700",
"DDInter785"
] | Somatrem | Fostamatinib | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural dispo... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
98,
24,
214
]
],
[
[
98,
63,
976
],
[
976,
24,
214
]
],
[
[
98,
24,
861
],
[
861,
63,
214
]
],
[
[
98,
64,
879
],
[
879,
24,
... | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
... | Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib and Ripret... |
DB00295 | DB00333 | 475 | 576 | [
"DDInter1244",
"DDInter1166"
] | Morphine | Methadone | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Major | 2 | [
[
[
475,
25,
576
]
],
[
[
475,
24,
194
],
[
194,
40,
576
]
],
[
[
475,
25,
1301
],
[
1301,
40,
576
]
],
[
[
475,
24,
1164
],
[
1164,
... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methadone"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
],
[
"Darifenacin",
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Methadone (Compound)
Morphine may lead to a major life threatening interaction when taken with Levacetylmethadol and Levacetylmethadol (Compound) resembles Methadone (Compound)
Morph... |
DB00280 | DB05679 | 494 | 1,683 | [
"DDInter575",
"DDInter1907"
] | Disopyramide | Ustekinumab | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
494,
24,
1683
]
],
[
[
494,
24,
1093
],
[
1093,
63,
1683
]
],
[
[
494,
25,
1250
],
[
1250,
63,
1683
]
],
[
[
494,
24,
617
],
[
617,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Disopyramide may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cau... |
DB01259 | DB08868 | 392 | 1,011 | [
"DDInter1024",
"DDInter737"
] | Lapatinib | Fingolimod | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
392,
25,
1011
]
],
[
[
392,
6,
8374
],
[
8374,
45,
1011
]
],
[
[
392,
21,
28792
],
[
28792,
60,
1011
]
],
[
[
392,
62,
1247
],
[
1247,... | [
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Lapatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Fingolimo... | Lapatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound)
Lapatinib (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Fingolimod (Compound)
Lapatinib may cause a minor interaction that can limit clinical effects when tak... |
DB00004 | DB06688 | 669 | 1,430 | [
"DDInter499",
"DDInter1677"
] | Denileukin diftitox | Sipuleucel-T | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
669,
24,
1430
]
],
[
[
669,
25,
676
],
[
676,
63,
1430
]
],
[
[
669,
24,
1531
],
[
1531,
24,
1430
]
],
[
[
669,
24,
713
],
[
713,
... | [
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Denileukin diftitox",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
... | Denileukin diftitox may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab ... |
DB01166 | DB14975 | 477 | 988 | [
"DDInter379",
"DDInter1949"
] | Cilostazol | Voxelotor | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
477,
24,
988
]
],
[
[
477,
63,
222
],
[
222,
23,
988
]
],
[
[
477,
63,
629
],
[
629,
24,
988
]
],
[
[
477,
25,
985
],
[
985,
24,... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimu... |
DB00009 | DB00533 | 1,271 | 1,416 | [
"DDInter56",
"DDInter1613"
] | Alteplase | Rofecoxib | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Moderate | 1 | [
[
[
1271,
24,
1416
]
],
[
[
1271,
25,
1409
],
[
1409,
63,
1416
]
],
[
[
1271,
64,
1578
],
[
1578,
24,
1416
]
],
[
[
1271,
24,
714
],
[
714... | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
... | Alteplase may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib
Alteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction t... |
DB00872 | DB11581 | 1,080 | 1,456 | [
"DDInter438",
"DDInter1926"
] | Conivaptan | Venetoclax | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
1080,
25,
1456
]
],
[
[
1080,
25,
1135
],
[
1135,
23,
1456
]
],
[
[
1080,
25,
1476
],
[
1476,
63,
1456
]
],
[
[
1080,
24,
86
],
[
86,
... | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may... | Conivaptan may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Conivaptan may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interact... |
DB11915 | DB11963 | 1,293 | 1,045 | [
"DDInter1909",
"DDInter465"
] | Valbenazine | Dacomitinib | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was devel... | Major | 2 | [
[
[
1293,
25,
1045
]
],
[
[
1293,
63,
1376
],
[
1376,
24,
1045
]
],
[
[
1293,
64,
384
],
[
384,
24,
1045
]
],
[
[
1293,
24,
710
],
[
710,
... | [
[
[
"Valbenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacomitinib"
]
],
[
[
"Valbenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Di... | Valbenazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Valbenazine may lead to a major life threatening interaction when taken with Idelalisib and Idelalis... |
DB06016 | DB09488 | 1,508 | 103 | [
"DDInter300",
"DDInter23"
] | Cariprazine | Acrivastine | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
1508,
24,
103
]
],
[
[
1508,
63,
85
],
[
85,
24,
103
]
],
[
[
1508,
24,
849
],
[
849,
24,
103
]
],
[
[
1508,
63,
85
],
[
85,
24,... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyram... |
DB01072 | DB12141 | 915 | 971 | [
"DDInter129",
"DDInter817"
] | Atazanavir | Gilteritinib | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
915,
25,
971
]
],
[
[
915,
25,
1135
],
[
1135,
23,
971
]
],
[
[
915,
24,
466
],
[
466,
62,
971
]
],
[
[
915,
64,
1181
],
[
1181,
... | [
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} m... | Atazanavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may caus... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.